COHANCE LIFESCIENCES (COHANCE) | Stock Overview & Key Data
COHANCE LIFESCIENCES Performance Comparison
Stock Range
Today's Range
Low: ₹925.00
High: ₹948.25
on August 8, 2025
52 Week Range
Low: ₹919.00
High: ₹1,123.40
on August 7, 2025
on May 8, 2025
All-Time High: ₹1,123.40 on May 5, 2025
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR356.9B
EPS
10.48
P/E Ratio (TTM)
89.01
Forward P/E
39.72
P/B Ratio
14.00
PEG Ratio
-8.21
Div. Yield
N/A
ROE
13.61%
Beta
0.644
Debt to Equity
15.16
Financial Highlights
Profitability
Gross Margin
66.67%
Operating Margin
11.64%
Profit Margin
22.37%
Returns and Earnings
Return on Assets (TTM)
7.04%
Return on Equity (TTM)
13.61%
EBITDA
INR4.3B
Net Income (TTM)
INR2.7B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR47.04
Quarterly Revenue Growth (YoY)
58.90%
Quarterly Earnings Growth (YoY)
-21.30%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| COHANCE LIFESCIENCES COHANCE | 356.88B Large-cap | -4.72% | -6.52% | -11.99% | -11.99% | -11.99% | -13.43% | -13.43% | -13.43% |
| Sun Pharmaceutical SUNPHARMA | 3.92T Large-cap | -2.63% | -5.12% | -10.20% | -8.38% | -16.03% | -8.55% | 73.73% | 198.65% |
| Divi's Laboratories DIVISLAB | 1.63T Large-cap | -7.03% | -14.75% | -0.77% | -0.41% | -2.61% | 22.45% | 58.73% | 91.42% |
| Cipla CIPLA | 1.20T Large-cap | -1.18% | -0.22% | -0.12% | 1.79% | 0.38% | 3.58% | 45.16% | 93.18% |
| Torrent TORNTPHARM | 1.22T Large-cap | -2.85% | 7.55% | 12.16% | 11.91% | 4.52% | 7.03% | 132.03% | 25.86% |
| Mankind Pharma MANKIND | 1.05T Large-cap | -3.87% | 1.46% | 1.13% | -1.40% | -14.37% | 15.49% | 76.92% | 76.92% |
Ownership & Short Interest
Insider Ownership
73.28%
Institutional Ownership
14.98%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
148K
Average 90-Day Volume
246K
COHANCE LIFESCIENCES Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in COHANCE LIFESCIENCES would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is COHANCE's 52-week high and low?
- In the last 52 weeks, COHANCE LIFESCIENCES reached a high of ₹1,123.40 (on May 8, 2025) and a low of ₹919.00 (on August 7, 2025).
- What is the market cap and P/E ratio for COHANCE?
- Curious about COHANCE LIFESCIENCES's size and valuation? Its market capitalization stands at 356.88B. When it comes to valuation, the P/E ratio (trailing twelve months) is 89.01, and the forward P/E (looking ahead) is 39.72.
- Does COHANCE pay dividends? If so, what's the yield?
- As for dividends, COHANCE LIFESCIENCES isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are COHANCE LIFESCIENCES's main competitors or similar companies to consider before investing?
When looking at COHANCE LIFESCIENCES, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.92T Healthcare Drug Manufacturers - Specialty & Generic -8.55% 73.73% Divi's Laboratories
DIVISLAB1.63T Healthcare Drug Manufacturers - Specialty & Generic 22.45% 58.73% Cipla
CIPLA1.20T Healthcare Drug Manufacturers - Specialty & Generic 3.58% 45.16% Torrent
TORNTPHARM1.22T Healthcare Drug Manufacturers - Specialty & Generic 7.03% 132.03% Mankind Pharma
MANKIND1.05T Healthcare Drug Manufacturers - Specialty & Generic 15.49% 76.92% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for COHANCE LIFESCIENCES LTD? (e.g., ROE, Debt/Equity)
- To get a sense of COHANCE LIFESCIENCES's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 13.61%, the Debt to Equity ratio from the most recent quarter is 15.16, and its Gross Profit Margin stands at 66.67%.
- What is the recent revenue and earnings growth for COHANCE?
- Looking at COHANCE LIFESCIENCES's growth, its revenue over the trailing twelve months (TTM) was INR12B. Compared to the same quarter last year (YoY), quarterly revenue grew by 58.90%, and quarterly earnings saw a YoY growth of -21.30%.
- How much of COHANCE stock is held by insiders and institutions?
- Wondering who owns COHANCE LIFESCIENCES stock? Company insiders (like executives and directors) hold about 73.28% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 14.98%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.